Interim results from the STOMP study show that the combination of selinexor, pomalidomide, and dexamethasone appears to offer relatively high overall response rates and encouraging progression-free survival in heavily pretreated patients with multiple myeloma.
Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis.
The IKEMA study interim analysis showed isatuximab + carfilzomib and dexamethasone resulted in a clinically meaningful improvement in depth of response, with more patients reaching minimal residual disease–negativity compared with carfilzomib and dexamethasone alone.
The updated analysis of the phase 1 study of teclistamab in patients with RRMM shows favorable efficacy and manageable safety, and supports the planned phase 2 monotherapy trial at 1500 μg/kg administered subcutaneously.
Results from a phase 1 study of talquetamab, a first-in-class bispecific antibody, show encouraging clinical activity with manageable toxicity in heavily pretreated patients with RRMM. The study is ongoing to identify a dose for phase 2 investigation.
This phase 1/2 study demonstrated favorable efficacy and low rates of toxicity with low doses of P-BCMA-101 CAR T-cells in patients with RRMM. The favorable safety profile prompted a protocol amendment to allow fully outpatient administration.
This updated analysis of a phase 1, first-in-human study of REGN5458 in heavily pretreated patients with RRMM is consistent with previous findings, showing an acceptable safety profile and deep and durable responses.
The analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) + dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging treatment efficacy that was well tolerated.
Results from a network meta-analysis demonstrated that triple therapy is superior to dual therapy for lenalidomide-refractory patients with multiple myeloma, with the highest efficacy achieved with triple therapy that included a monoclonal antibody.
Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab + Pd reduced the risk for disease progression and death without additional safety signals for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.